RxDoctor Payments Data

Syed Hussain, MD

Nephrology · Galveston, TXNPI 1750674842

Payments from drug & device makers

$2,565in general payments, 2019–2025

Across 65 payments — averaging $39.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mozarc Medical US LLC$1K
  • Boston Scientific$491
  • Mallinckrodt Hospital Products Inc.$141
  • Medtronic$135
  • Travere Therapeutics, Inc.$119
  • Amgen$85
  • plus $481 from 10 others

What the payments were for

  • Travel & lodging$1,08242%
  • Food & beverage$1,48358%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,565 in reported general payments places this provider in the 55th percentile of 1,070 nephrology providers in Texas.

See all nephrology providers in Texas

Medicare billing

Part B allowed, 2024
$117,369
Medicare patients
304
Services billed
1,149

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NulojixBelatacept19$32,486
JardianceEmpagliflozin19$13,995
Valganciclovir Hcl64$12,312
Mycophenolic AcidMycophenolate Sodium31$9,569
FarxigaDapagliflozin Propanediol11$8,188
Cinacalcet Hcl54$7,332
Envarsus XrTacrolimus17$6,825
Tacrolimus47$4,499
Sevelamer Carbonate14$2,163
Nifedipine ErNifedipine26$1,338
Prednisone238$839
Calcium Acetate13$479
Mycophenolate Mofetil16$431
Famotidine77$422
Furosemide66$381

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$42$13,99519 claims
AstraZenecaFarxiga$66$8,18811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,070 nephrology providers in Texas.

Other nephrology in Galveston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →